Welcome to our dedicated page for Oramed Pharmaceuticals news (Ticker: ORMP), a resource for investors and traders seeking the latest updates and insights on Oramed Pharmaceuticals stock.
Oramed Pharmaceuticals Inc. (ORMP) generates news at the intersection of clinical-stage drug development, oral delivery technology, and strategic healthcare investments. The company describes itself as a platform technology pioneer in oral delivery solutions for drugs currently delivered via injection, centered on its Protein Oral Delivery (POD™) technology and a refined oral insulin program.
News about Oramed often covers clinical and strategic milestones for its oral insulin and POD™ platform, including updates on trial design, analysis of Phase 2 and Phase 3 data, and plans for U.S.-based clinical studies. Company letters to shareholders and press releases provide context on how Oramed is advancing its oral insulin program independently and how it evaluates high-responder subgroups in its clinical data.
Another major source of headlines is Oramed’s investment and partnership activity across the biomedical and medical technology landscape. Releases have detailed structured financings and royalty arrangements with Scilex Holding Company, a substantial equity investment and strategic collaboration with Alpha Tau Medical Ltd., and positions in companies such as BioXcel Therapeutics Inc. and Pelthos Therapeutics Inc. These updates often discuss repayments, warrant structures, royalty interests, and unrealized gains.
Recent news also highlights transformative corporate transactions, such as the announced transfer of Oramed’s POD™ technology to Lifeward Ltd. in exchange for a significant beneficial ownership interest and participation in a revenue-generating medical robotics business. Additional items include stock repurchase programs, cash dividend declarations, and the adoption of a Rights Agreement involving common stock purchase rights.
Investors and followers of ORMP news can use this page to review Oramed’s press releases, shareholder letters, and transaction announcements in one place, tracking developments in its oral drug delivery platform, strategic investments, and corporate actions over time.
Oramed Pharmaceuticals reported positive outcomes from its Phase 2 trial of ORMD-0801, an oral insulin for Type 2 Diabetes patients with NASH, conducted with 32 patients over 12 weeks. Primary endpoint met: ORMD-0801 showed safety and tolerability at 8 mg twice daily. Secondary endpoint met: Demonstrated a significant reduction in liver fat content, suggesting its potential to treat NASH effectively. The firm anticipates forthcoming results from its Phase 3 trial in January 2023, highlighting the importance of ORMD-0801 in addressing a serious unmet medical need.
Oramed Pharmaceuticals (Nasdaq: ORMP) announced that CEO Nadav Kidron will present an overview of the company at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 3:00 p.m. ET, in New York. The presentation will highlight Oramed’s innovations in oral drug delivery systems, particularly its lead candidate, ORMD-0801, aimed at transforming diabetes treatment. The presentation will be accessible for 90 days via a provided link.
Oramed Pharmaceuticals announced that its Phase 3 trial, ORA-D-013-2, has reached over 50% enrollment of the targeted 450 patients for its oral insulin capsule, ORMD-0801, aimed at treating type 2 diabetes. This trial follows the completion of enrollment for the larger ORA-D-013-1 trial, which involved 710 patients. The trials mark the first Phase 3 oral insulin studies conducted under FDA oversight. The primary goal of ORA-D-013-2 is to assess the efficacy of ORMD-0801 compared to placebo in improving glycemic control over a 26-week period.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced that it will provide a company overview and updates at the Canaccord Genuity Annual Growth Conference in Boston, Massachusetts, from August 8-11, 2022. The presentation is scheduled for August 10 at 4:30 p.m. E.T. and will be webcasted, with a link available on the Oramed website 48 hours prior. Oramed focuses on oral drug delivery systems and aims to revolutionize diabetes treatment with its lead candidate, ORMD-0801, currently in pivotal Phase 3 studies.
Oramed Pharmaceuticals reported a strong financial position with $169 million in cash and no debt as of March 31, 2022. The company expects pivotal Phase 3 oral insulin data in January 2023 and Phase 2 NASH data soon. ORMD-0801 aims to revolutionize type 2 diabetes treatment, offering a non-injection method beneficial to patients. Additionally, Oravax's Phase 1 clinical trial for an oral COVID-19 vaccine is underway in South Africa, with top-line data expected later this year. Oramed feels well-positioned for upcoming milestones despite broader market challenges.
Oramed Pharmaceuticals (Nasdaq: ORMP) announced the addition of Dr. Anne Peters to its Scientific Advisory Board on June 1, 2022. Dr. Peters, a leading expert in diabetes care, brings extensive experience in clinical diabetes programs and research. She has authored over 200 publications and has been involved in over 40 research studies. The company is advancing its pivotal Phase 3 studies for ORMD-0801, the first oral insulin capsule aimed at transforming diabetes treatment. This strategic appointment aims to enhance Oramed's scientific direction and development capabilities.
Oramed Pharmaceuticals (Nasdaq: ORMP) announced a significant achievement on May 24, 2022, as the US Patent and Trademark Office granted them a patent for methods and compositions aimed at treating diabetes mellitus. This patent covers oral pharmaceutical solutions that combine insulin with Glucagon-like Peptide 1 (GLP-1). Oramed is pioneering oral delivery systems to transform diabetes treatment, particularly with its lead candidate, ORMD-0801, currently in pivotal Phase 3 trials, along with the development of an oral GLP-1 analog capsule, ORMD-0901.
Oramed Pharmaceuticals (Nasdaq:ORMP) announced that CEO Nadav Kidron will present a company overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, in Miami, Florida. The presentation is set for 12:00 p.m. E.T. and will be available for streaming for 90 days. Known for its oral drug delivery innovations, Oramed aims to transform diabetes treatment with its lead candidate, ORMD-0801, currently in Phase 3 trials.
Oramed Pharmaceuticals has completed enrollment for its Phase 3 ORA-D-013-1 study of the oral insulin capsule, ORMD-0801, with 710 patients, exceeding the initial goal of 675. This study focuses on type 2 diabetes patients with inadequate glycemic control, aiming for efficacy results in January 2023. The oral insulin could significantly improve patient experience and outcomes compared to injectable insulin, potentially becoming the first FDA-approved oral insulin.
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) has received a patent from the European Patent Office for its innovative methods to treat non-alcoholic fatty liver disease (NAFLD) and hepatic steatosis. This patent complements a previously granted U.S. patent and is pending approval in various key markets. Additionally, Oramed has successfully completed 100% enrollment in its Phase 2 trial for oral insulin ORMD-0801, targeting type 2 diabetes patients with non-alcoholic steatohepatitis (NASH). The NASH drug market is projected to reach $84 billion by 2029.